Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Qingyan Li

Sichuan University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · JOURNAL ARTICLE

Optimizationof a Series of Novel 1 H -Pyrrolo[3,2- c ]pyridine-Based USP1Inhibitors with Potent In Vivo Antitumor Activity

Journal of Medicinal Chemistry

Early-stage preclinical chemistry and pharmacology study demonstrating lead compound design and in vivo efficacy in xenograft models, without clinical trial data or regulatory approval.

PreliminaryMinghai Tang Qingyan Li Protein Degradation and Inhibitors

Reported

Tumor inhibition rate (38a + olap…80.7%

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support